SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community highlights its recently achieved ISO 20022 compliance, a significant step positioning the project for integration with global financial standards. Investors are actively discussing ZBCN's potential as a utility token, drawing comparisons to early-stage assets like XRP and XLM due to its robust regulatory framework and expanding partnerships in real-time payments and payroll. This compliance-first approach, alongside upcoming features like its Super App, fuels long-term bullish sentiment despite current market fluctuations.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is currently a major talking point within the crypto community, driven by significant optimism for its performance in the coming year, particularly 2026. Many foresee a substantial breakout, with conversations highlighting the perceived end of its 4-year cycle and strong expectations for considerable gains. Investors are actively discussing accumulation strategies and Litecoin's long-standing utility as "digital silver" in the broader cryptocurrency market.

English version Introducing SWFTCoin (SWFTC) $SWFTC: Powering SWFT Blockchain and AI Services (SWFTGPT)  SwftCoin ($SWFTC) is the native utility token driving SWFT Blockchain's AI-powered ecosystem, SWFTGPT, and the first ever AI token featured on Coinbase. SWFTGPT is also the first domain-specific LLM for crypto.  SwftCoin key features include: 50% Reduced Transaction Fees: Lower costs on all transactions. AI Service Payments: Use $SWFTC to access SWFTGPT. Tools include expert market analysis,  predictions, and intelligent trading solutions.  Membership Benefits: Unlock premium features and AI agent services within SWFTGPT. AI-Powered Swaps: Enable precise, fast cross-chain transactions and analytics. SWFT Blockchain combines AI innovation with blockchain infrastructure, simplifying crypto trading while enhancing functionality through $SWFTC.   Chinese version $SWFTC：驱动 SWFT Blockchain 和 AI 服务（SWFTGPT） SwftCoin ($SWFTC) 是 SWFT Blockchain 的原生实用代币，为其 AI 驱动的生态系统 SWFTGPT 提供支持，同时也是 Coinbase 上首个 AI 代币。SWFTGPT 也是首个专注于加密领域的特定领域大型语言模型 (LLM)。 SwftCoin 的主要功能包括： 1、50% 交易费减免：降低所有交易成本。 2、AI 服务支付：使用 $SWFTC 访问 SWFTGPT 工具，包括专家市场分析、预测以及智能交易解决方案。 3、会员权益：解锁 SWFTGPT 的高级功能和 AI 代理服务。 4、AI 驱动的闪兑：实现精准快速的跨链交易和数据分析。 SWFT Blockchain 将 AI 创新与区块链基础设施结合，通过 $SWFTC 简化加密交易，并提升其功能性。

SwftCoin

SwftCoin (SWFTC) is currently a top trending crypto, fueled by community excitement surrounding potential new major exchange listings, particularly Coinbase, and a notable surge in trading volume. Investors are actively discussing its fully diluted supply, AI-integrated exchange, and crucial cross-chain bridging technology, anticipating substantial "altseason" gains and its pivotal role in the evolving multi-chain ecosystem.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid a strong community debate, with many anticipating a broader "alt season" and "return of the memes" after a period of market decline. While some express strong confidence and are actively accumulating, others view the token with skepticism, citing its past performance and questioning its long-term viability as a meme coin.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics is trending after announcing a significant corporate restructuring, including workforce reductions and a strategic review, leading to speculation about its future and perceived undervaluation. The community is actively discussing its extremely low share float, positioning it as a prime short-squeeze candidate with high speculative interest for a substantial upward move. Many compare it to other recent volatile runners, anticipating significant price appreciation.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is actively trending amidst a highly polarized community reacting to recent price movements. While many express strong bearish sentiment and label it as a 'scam,' a significant portion of holders views current levels as a prime 'buying opportunity,' anticipating substantial future gains. The ongoing conversation frequently compares its performance and potential within the broader meme coin market.

Pixelworks, Inc. engages in the design and development of integrated circuits used in electronic display devices. It offers consumer electronics and professional display products, video delivery, and streaming solutions for content service providers. Its product categories consist of ImageProcessor integrated circuits (ICs), video co-processor ICs, and transcode ICs. The company was founded by Allen H. Alley, Michael G. West, Kenneth Hunkins, Robert Y. Greenberg and Bradley A. Zenger in 1997 and is headquartered in Portland, OR.

Pixelworks Inc

Pixelworks (PXLW) is trending due to ongoing discussions around the confirmed sale of its Shanghai subsidiary, which is proceeding despite a failed shareholder supermajority vote after the Board utilized a legal provision. This has led to community conversations about a potential arbitrage opportunity, given the perceived undervaluation relative to the expected cash injection, and an increasing focus on the long-term potential of its TrueCut Motion technology following a multi-year agreement with Disney.

Zoracles

Zoracles is drawing significant attention for its role in the creator economy, with recent viral news driving a creator coin surge on its platform. The community is buzzing about Zora's long-term potential as an application-specific currency within the Coinbase Base ecosystem, highlighting its utility for content creators and its non-experimental asset status. Despite ongoing market volatility, many anticipate a substantial rally, with discussions centered on accumulation and upcoming market catalysts.

The Graph is an indexing protocol and global API for organizing blockchain data and making it easily accessible with GraphQL. Developers can use Graph Explorer to search, find, and publish all the public data they need to build decentralized applications. The Graph Network makes it possible to build serverless dApps that run entirely on public infrastructure.  GRT is the native token of the network that’s used to coordinate work. GRT is an ERC20 token. Node operators, called Indexers, stake and earn GRT for processing queries. Anyone can delegate GRT to Indexers to secure the network and earn rewards. Curators organize data on The Graph by signaling GRT on useful APIs, called subgraphs. Indexers, Delegators, and Curators work together to organize the data for the crypto economy and maintain a useful global API for DeFi and Web3.

The Graph

The Graph ($GRT) is attracting attention amid expanded utility, including cross-chain staking capabilities on Solana, Arbitrum, and Base, along with institutional interest through its Amp Enterprise Database integration with DTCC. While some in the community express frustration over past price action, many are actively accumulating, believing its role as a foundational data layer for Web3 and AI positions it for significant future growth in a potential altcoin rally.

Aerodrome Finance is a next-generation AMM designed to serve as Base's central liquidity hub, combining a powerful liquidity incentive engine, vote-lock governance model, and friendly user experience. Aerodrome inherits the latest features from Velodrome V2.

Aerodrome Finance

Aerodrome Finance is a major talking point as its recent Robinhood listing and upcoming merger to form a cross-chain "super-DEX" spark significant community debate. While many investors are bullish on its potential as the primary liquidity hub for the growing Base ecosystem, supported by protocol revenue surpassing emissions and strategic buybacks, others remain concerned about token dilution and market volatility. This creates a highly divided sentiment surrounding its future trajectory within the altcoin market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher - Here's What Happened

Actuate Therapeutics (NASDAQ:ACTU) Trading 2.7% Higher - Time to Buy...

Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU

Voss Capital LP grew its position in Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 101.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 286,140...

How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%

The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BIOS Capital Management LP Buys 71,428 Shares of Actuate Therapeutics, Inc. $ACTU

BIOS Capital Management LP raised its stake in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F...

What is HC Wainwright's Estimate for ACTU FY2025 Earnings?

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Actuate Therapeutics in a research report issued on Wednesday...

HC Wainwright Has Negative Forecast for ACTU FY2029 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - HC Wainwright reduced their FY2029 EPS estimates for shares of Actuate Therapeutics in a note issued to investors on Wednesday, November 19th...

Actuate Therapeutics (NASDAQ:ACTU) Shares Up 0.5% After Better-Than-Expected Earnings

Actuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.5% Following Strong Earnings...

Actuate Therapeutics (NASDAQ:ACTU) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) announced its earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus...

Actuate Therapeutics, Inc. (ACTU) announced on Monday that it has amended its application to the U.S. Food and Drug Administration (FDA) for its lead investigational drug Elraglusib in the treatment of pancreatic cancer.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/22/3153932/0/en/Actuate-Therapeutics-Provides-FDA-with-Updated-Clinical-Data-Package-to-Support-Planned-Regulatory-Interactions-with-FDA-and-EMA-Over-the-Coming-Months.html">stated</a> that it has amended the investigational new drug (IND) application with updated clinical data from its ongoing international mid-stage trial of the drug in the first-line treatment of metastatic pancreatic cancer. The study showed a statistically significant improvement in median overall survival with the combination arm of Elraglusib plus Gemcitabine/nab-paclitaxel (GnP) versus GnP alone, in addition to a 37% reduction in the risk of death.The data is intended to support planned regulatory submissions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) beginning later this year and continuing into early 2026, the company said. It also added that the data strengthens the case for Elraglusib as a back-bone therapy that can be combined with different regimens used to treat pancreatic cancer.The company is currently studying Elraglusib in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapies.<a href="https://stocktwits.com/symbol/ACTU">ACTU shares</a> traded 6% higher at the time of writing. On Stocktwits, retail sentiment around ACTU jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_11_15_37_AM_png_49248344ea.webp" alt="ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Actuate also stated that its recent $17.25 million public offering provides an extended runway into the second half of 2026.“We have already updated the clinical data package on file with the FDA, and during the remainder of this year and into the first quarter of 2026, we expect to gain clarity on Elraglusib’s regulatory path forward for the first-line treatment of metastatic PDAC,” said CEO Daniel Schmitt.ACTU stock is down by 11% this year but up by 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-rallies-after-piper-sandler-hikes-price-target/chDQA76R32Z">Tesla Stock Rallies After Piper Sandler Hikes Price Target – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer

Actuate on Monday also said that its recent $17.25 million public offering provides an extended runway into the second half of 2026. 

ACTU
Actuate Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACTU News

ACTUActuate Therapeutics Inc.